PetVivo Reports Third Quarter of Fiscal 2023 Financial Results
EDINA, MN , Feb. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the third quarter of fiscal 2023. The Company began commercialization of its lead product Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021.
- Conference call begins at 4:00 p.m. Central time today
EDINA, MN , Feb. 09, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the third quarter of fiscal 2023. - John Lai, CEO, commented, “I’m excited about our team’s performance in the third quarter of fiscal 2023 highlighted by revenues of $510,109 as compared to $51,004 in the same period a year ago.
- Product shipments to MWI increased to $456,502 in the third quarter as compared to $118,264 in the second quarter of 2023.
- In January 2023, we entered into a lease agreement for approximately 14,000 square feet of production and warehouse space in Edina, Minnesota.